Screening and Construction of Probiotic Strains with Enhanced Protective Properties against Intestinal Disorders

Article English OPEN
Mercenier, A. ; Hols, P. ; Roussel, Y. ; Perez-Martinez, G. ; Buesa, J. ; Wilks, M. ; Pozzi, G. ; Remaut, E. ; Morelli, L. ; Grangette, C. ; Monedero, V. ; Palumbo, E. ; Foligne, B. ; Steidler, L. ; Nutten, S. (2011)
  • Publisher: Microbial Ecology in Health and Disease
  • Journal: Microbial Ecology in Health and Disease (issn: 1651-2235, eissn: 1651-2235)
  • Related identifiers: doi: 10.3402/mehd.v16i2-3.7942

Within the scope of the DEPROHEALTH project, a range of wild-type strains of Lactobacillus were analysed for their ability to interact with the host immune system. While the studied isolates interacted in a strain-specific way with immune cells, they seemed to have little and non-discriminative effect on epithelial cells. However, they were shown to facilitate the cross-talk between intestinal and immune cells. Studies conducted in mouse colitis models confirmed that specific strains possess higher intrinsic anti-inflammatory properties. Two of these were further engineered to produce murine IL10 and are presently being evaluated for their protective effect in a TNBS colitis model. Cell wall mutants of Lactobacillus plantarum NCIMB8826 were analysed for their phenotypic traits, immune modulatory ability and capacity to act as live carriers. This led to the identification of mutants with increased anti-inflammatory or antigen delivery properties. Substantial work was invested in attempts to increase the immune response induced by recombinant lactobacilli producing Helicobacter or rotavirus antigens. In the course of these experiments, new methods to evaluate the load of Helicobacter in infected mice were developed. Novel targeting signals for cell surface presentation of therapeutic molecules were also identified. Finally, a safe biologically contained lactococcal strain secreting human IL10 was constructed, thus opening the way to a first clinical trial in patients suffering from inflammatory bowel disease (IBD).Key words: probiotics, immune modulation, inflammatory bowel disease, rotavirus, Helicobacter pylori .
  • References (33)
    33 references, page 1 of 4

    1. Mercenier A, Pavan S, Pot B. Probiotics as biotherapeutic agents: present knowledge and future prospects. Curr Pharm Des 2003; 9: 175 /91.

    2. Fernandez MF, Boris S, Barbes C. Probiotic properties of human lactobacilli strains to be used in the gastrointestinal tract. J Appl Microbiol 2003; 94: 449 /55.

    3. Christensen HR, Frokiaer H, Pestka JJ. Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells. J Immunol 2002; 168: 171 /8.

    4. Hershberg RM, Mayer LF. Antigen processing and presentation by intestinal epithelial cells /polarity and complexicity. Immunol Today 2000; 21: 123 /8.

    5. Haller D, Bode C, Hammes WP, Pfeifer AM, Schiffrin EJ, Blum S. Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leukocyte co-cultures. Gut 2000; 47: 79 /87.

    6. Wallace JL, MacNaughton WK, Morris G, Beck PL. Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology 1989; 96: 29 /36.

    7. Neurath M, Fuss I, Strober W. TNBS-colitis. Int Rev Immunol 2000; 19: 51 /62.

    8. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000; 289: 1352 /5.

    9. van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin-10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology 1997; 113: 383 /9.

    10. Marteau P, Seksik P, Jian R. Probiotics and health: new facts and ideas. Curr Opin Biotechnol 2002; 13: 486 /9.

  • Metrics
    No metrics available
Share - Bookmark